Related Experiment Videos
Severe hyperphosphatemia resulting from high-dose liposomal amphotericin in a child with leukemia
1Department of Pediatrics, University of California, Davis, California 95817, USA.
Insights
Children with acute lymphoblastic leukemia (ALL) can develop severe hyperphosphatemia from liposomal amphotericin B. Early recognition of this risk is crucial for preventing serious complications in pediatric cancer patients.
Area of Science:
- Pediatric Oncology
- Nephrology
- Pharmacology
Background:
- Children with acute lymphoblastic leukemia (ALL) face risks of electrolyte imbalances.
- Management of ALL often involves treatments that can affect electrolyte levels.
Observation:
- A case of severe hyperphosphatemia in a child with ALL is presented.
- This complication arose following administration of high-dose liposomal amphotericin B.
Findings:
- High-dose liposomal amphotericin B can cause a significant exogenous phosphorus load.
- Severe hyperphosphatemia is a potentially life-threatening consequence.
Implications:
- Healthcare providers must be aware of this adverse effect of liposomal amphotericin B.
- Prompt diagnosis and management are essential to mitigate morbidity in pediatric patients.
- This highlights the importance of vigilant electrolyte monitoring during treatment for ALL.
Abstract:
Children with acute lymphoblastic leukemia (ALL) are at risk for serious electrolyte abnormalities. The authors report their experience in managing a child with ALL who developed severe hyperphosphatemia as a consequence of a large exogenous load of phosphorus from high-dose liposomal amphotericin B. Health care providers need to recognize this potentially life-threatening complication of liposomal amphotericin B, since early detection and intervention can prevent significant morbidity.